Information Provided By: 
Fly News Breaks for December 18, 2015
IONS, ISIS
Dec 18, 2015 | 15:25 EDT
Piper Jaffray analyst Joshua Schimmer believes Isis Pharmaceuticals' decision to change its name to Ionis Pharmaceuticals is the first step in improving its positioning with investors and he is optimistic that sentiment can shift for the better. The analyst, who sees a number of catalysts on the horizon in 2016 and 2017 for Ionis, keeps an Overweight rating and $80 price target on the stock.
News For ISIS;IONS From the Last 2 Days
There are no results for your query ISIS;IONS
